Secondary CVD Prevention Requires Much More than "Usual Care," Says Michael Koren, MD,
ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.
"It's sobering," Michael Koren, MD, primary investigator of the VICTORION-INITIATE study said while speaking with Patient Care, referring to how few individuals with ASCVD who are taking maximum doses of statins have not met guideline-recommended targets for LDL-C. The strategies inherent in a "usual care" approach to treating ASCVD, he added, "are just not cutting it." Koren also said that "effective non-statin therapies [are] being markedly underutilized." V-INITIATE explored a systematic, structured approach to lipid lowering in high risk patients that could offer potential solutions.
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study, is a cardiologist and serves as the chief executive officer at ENCORE Research Group, in Jacksonville, FL. Koren founded ENCORE in 1997 and since then the organization has conducted more than 2500 clinical trials across 8 locations in Florida.
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
